• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Richards Steven M

    8/13/25 12:33:45 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SHPH alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Richards Steven M

    (Last) (First) (Middle)
    C/O SHUTTLE PHARMACEUTICALS HOLDINGS
    401 PROFESSIONAL DRIVE, SUITE 260

    (Street)
    GAITHERSBURG MD 20879

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Shuttle Pharmaceuticals Holdings, Inc. [ SHPH ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    08/08/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Unit (1) 08/08/2025 A 29,240 (2) (2) Common Stock 29,240 $0 29,240 D
    Explanation of Responses:
    1. Each Restricted Stock Unit ("RSU"s) represents the contingent right to receive one share of common stock.
    2. One-third of these RSUs will vest on each of 08/08/2026, 08/08/2027 and 08/08/2028.
    /s/ Steven M Richards 08/12/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SHPH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SHPH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SHPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Shuttle Pharmaceuticals Acquires AI Health Platform

    Rockville, Maryland--(Newsfile Corp. - November 21, 2025) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle" or the "Company") today announced that it has closed the acquisition of the assets and liabilities of 1542770 B.C. Ltd. d/b/a Molecule.ai ("Molecule"), a Canadian artificial intelligence company specializing in molecular discovery and drug development technologies.Under the terms of the agreement, 1563868 B.C. Ltd., a wholly owned subsidiary of Shuttle, acquired substantially all of Molecule's assets and liabilities for a total purchase price of $8 million, payable in a combination of cash and shares of Shuttle common stock, plus an additional contingent $2 million, pay

    11/21/25 9:30:00 AM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shuttle Pharmaceuticals Announces Above-the-Market $2.5 Million Private Placement at Effective Price per Share of $4.00

    Gaithersburg, Maryland--(Newsfile Corp. - November 3, 2025) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma" or the "Company"), today announced that it entered into a securities purchase agreement with a single investor for aggregate gross proceeds of approximately $2.5 million (the "Offering"), before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the Offering for marketing, general corporate purposes and working capital purposes.In connection with the Offering, the Company will issue a pre-funded warrant to purchase up to 625,156 shares of common stock at an effective purchas

    11/3/25 7:00:00 AM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shuttle Pharmaceuticals to Acquire AI Molecular Modeling and Predictive Analytics Platform

    Rockville, Maryland--(Newsfile Corp. - October 21, 2025) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle" or the "Company") today announced that it has entered into a binding term sheet with 1542770 BC Ltd. ("Molecule"), a Canadian artificial intelligence company specializing in molecular discovery and drug development technologies.Under the terms of the agreement, Shuttle or one of its affiliates will acquire substantially all of Molecule's assets and liabilities for a total purchase price of $10 million, payable in a combination of cash and shares of Shuttle common stock. The exact mix of cash and equity will be determined by Shuttle at its sole discretion and will be paid

    10/21/25 4:05:00 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SHPH
    SEC Filings

    View All

    Shuttle Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

    11/28/25 5:31:14 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shuttle Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

    11/26/25 12:28:39 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shuttle Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits

    8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

    11/21/25 4:05:45 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SHPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Liriano Angel claimed no ownership of stock in the company (SEC Form 3)

    3 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)

    10/29/25 2:05:48 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Pathigoda Arachchige Sachin Eranga claimed no ownership of stock in the company (SEC Form 3)

    3 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)

    10/28/25 4:06:00 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Chambers Adam V claimed no ownership of stock in the company (SEC Form 3)

    3 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)

    9/8/25 5:15:26 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SHPH
    Leadership Updates

    Live Leadership Updates

    View All

    Shuttle Pharmaceuticals Acquires AI Health Platform

    Rockville, Maryland--(Newsfile Corp. - November 21, 2025) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle" or the "Company") today announced that it has closed the acquisition of the assets and liabilities of 1542770 B.C. Ltd. d/b/a Molecule.ai ("Molecule"), a Canadian artificial intelligence company specializing in molecular discovery and drug development technologies.Under the terms of the agreement, 1563868 B.C. Ltd., a wholly owned subsidiary of Shuttle, acquired substantially all of Molecule's assets and liabilities for a total purchase price of $8 million, payable in a combination of cash and shares of Shuttle common stock, plus an additional contingent $2 million, pay

    11/21/25 9:30:00 AM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors

    GAITHERSBURG, Md., June 04, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the appointment of George Scorsis as the Chairman of the Board of Directors. Mr. Scorsis has served as director of the Company since February 2025. Mr. Scorsis has over 25 years of experience leading companies in highly regulated industries to rapid growth, including alcohol, energy drinks, and Biotech. From October 2015 to July 2017, Mr. Scorsis worked as President at Mettrum Heal

    6/4/25 4:01:00 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities

    GAITHERSBURG, Md., March 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the appointment of Christopher Cooper as interim Co-Chief Executive Officer focused on enhancing the Company's capital markets and business capabilities. Dr. Anatoly Dritschilo, Chairman of the Company's Board of Directors, will continue in his role as Co-CEO overseeing the Company's scientific and clinical trial activities. "I am excited to welcome Christopher Cooper as Co-CEO of

    3/12/25 6:20:00 AM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SHPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Shuttle Pharmaceuticals Holdings Inc. (Amendment)

    SC 13G/A - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Subject)

    10/17/23 6:57:47 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Shuttle Pharmaceuticals Holdings Inc.

    SC 13G - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Subject)

    5/30/23 5:30:57 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care